Reuters logo
BRIEF-Antibe Therapeutics announces enrollment of first subjects in Phase 2B GI safety study for lead drug, ATB-346
September 8, 2017 / 11:16 AM / 2 months ago

BRIEF-Antibe Therapeutics announces enrollment of first subjects in Phase 2B GI safety study for lead drug, ATB-346

Sept 8 (Reuters) - Antibe Therapeutics Inc

* Antibe Therapeutics Inc - ‍enrollment commenced for key phase 2B GI safety study for ATB-346, remain on previously announced schedule​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below